Trials / Recruiting
RecruitingNCT06818474
Lanadelumab in Long-term Prophylaxis of Acquired Angioedema
- Status
- Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 5 (estimated)
- Sponsor
- Bernstein Clinical Research Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
use of lanadelumab in patients with acquired angioedema
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Lanadelumab 300 mg | no other intervention |
Timeline
- Start date
- 2024-06-01
- Primary completion
- 2027-09-01
- Completion
- 2027-12-01
- First posted
- 2025-02-10
- Last updated
- 2025-02-25
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06818474. Inclusion in this directory is not an endorsement.